Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oleclumab - AstraZeneca

Next Previous
Drug Profile

Oleclumab - AstraZeneca

Alternative Names: Anti-CD73 mAb - AstraZeneca; Anti-CD73 monoclonal antibody - AstraZeneca; MEDI-9447

Latest Information Update: 10 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; MedImmune
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Pancreatic cancer; Sarcoma
  • Phase I Solid tumours
  • Discontinued Bladder cancer; Colorectal cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 28 Aug 2025 Montefiore Medical Center plans a phase II trial for Non small cell lung cancer (Recurrent, First line therapy, Late stage disease, Combination therapy) in the USA (IV) (NCT07146230)
  • 19 Sep 2024 AstraZeneca plans a phase II study for Non small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Combination therapy) in Russia (IV, Infusion) (NCT06606847)
  • 13 Sep 2024 Efficacy and adverse events data from phase-II clinical trials in Breast cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top